Genomic and oncoproteomic advances in detection and treatment of colorectal cancer.

Hdl Handle:
http://hdl.handle.net/10147/207359
Title:
Genomic and oncoproteomic advances in detection and treatment of colorectal cancer.
Authors:
McHugh, Seamus M; O'Donnell, Jill; Gillen, Peter
Affiliation:
Dept. of Surgery, Our Lady of Lourdes Hospital, Drogheda, County Louth, Ireland. , seamusmchugh@rcsi.ie
Citation:
World J Surg Oncol. 2009 Apr 1;7:36.
Journal:
World journal of surgical oncology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207359
DOI:
10.1186/1477-7819-7-36
PubMed ID:
19338662
Abstract:
AIMS: We will examine the latest advances in genomic and proteomic laboratory technology. Through an extensive literature review we aim to critically appraise those studies which have utilized these latest technologies and ascertain their potential to identify clinically useful biomarkers. METHODS: An extensive review of the literature was carried out in both online medical journals and through the Royal College of Surgeons in Ireland library. RESULTS: Laboratory technology has advanced in the fields of genomics and oncoproteomics. Gene expression profiling with DNA microarray technology has allowed us to begin genetic profiling of colorectal cancer tissue. The response to chemotherapy can differ amongst individual tumors. For the first time researchers have begun to isolate and identify the genes responsible. New laboratory techniques allow us to isolate proteins preferentially expressed in colorectal cancer tissue. This could potentially lead to identification of a clinically useful protein biomarker in colorectal cancer screening and treatment. CONCLUSION: If a set of discriminating genes could be used for characterization and prediction of chemotherapeutic response, an individualized tailored therapeutic regime could become the standard of care for those undergoing systemic treatment for colorectal cancer. New laboratory techniques of protein identification may eventually allow identification of a clinically useful biomarker that could be used for screening and treatment. At present however, both expression of different gene signatures and isolation of various protein peaks has been limited by study size. Independent multi-centre correlation of results with larger sample sizes is needed to allow translation into clinical practice.
Language:
eng
MeSH:
Colorectal Neoplasms/chemistry/*diagnosis/genetics/*therapy; DNA Methylation; Electrophoresis, Gel, Two-Dimensional; *Genomics; Humans; Neoplasm Proteins/*analysis; *Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Markers, Biological/analysis
ISSN:
1477-7819 (Electronic); 1477-7819 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMcHugh, Seamus Men_GB
dc.contributor.authorO'Donnell, Jillen_GB
dc.contributor.authorGillen, Peteren_GB
dc.date.accessioned2012-02-01T10:21:29Z-
dc.date.available2012-02-01T10:21:29Z-
dc.date.issued2012-02-01T10:21:29Z-
dc.identifier.citationWorld J Surg Oncol. 2009 Apr 1;7:36.en_GB
dc.identifier.issn1477-7819 (Electronic)en_GB
dc.identifier.issn1477-7819 (Linking)en_GB
dc.identifier.pmid19338662en_GB
dc.identifier.doi10.1186/1477-7819-7-36en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207359-
dc.description.abstractAIMS: We will examine the latest advances in genomic and proteomic laboratory technology. Through an extensive literature review we aim to critically appraise those studies which have utilized these latest technologies and ascertain their potential to identify clinically useful biomarkers. METHODS: An extensive review of the literature was carried out in both online medical journals and through the Royal College of Surgeons in Ireland library. RESULTS: Laboratory technology has advanced in the fields of genomics and oncoproteomics. Gene expression profiling with DNA microarray technology has allowed us to begin genetic profiling of colorectal cancer tissue. The response to chemotherapy can differ amongst individual tumors. For the first time researchers have begun to isolate and identify the genes responsible. New laboratory techniques allow us to isolate proteins preferentially expressed in colorectal cancer tissue. This could potentially lead to identification of a clinically useful protein biomarker in colorectal cancer screening and treatment. CONCLUSION: If a set of discriminating genes could be used for characterization and prediction of chemotherapeutic response, an individualized tailored therapeutic regime could become the standard of care for those undergoing systemic treatment for colorectal cancer. New laboratory techniques of protein identification may eventually allow identification of a clinically useful biomarker that could be used for screening and treatment. At present however, both expression of different gene signatures and isolation of various protein peaks has been limited by study size. Independent multi-centre correlation of results with larger sample sizes is needed to allow translation into clinical practice.en_GB
dc.language.isoengen_GB
dc.subject.meshColorectal Neoplasms/chemistry/*diagnosis/genetics/*therapyen_GB
dc.subject.meshDNA Methylationen_GB
dc.subject.meshElectrophoresis, Gel, Two-Dimensionalen_GB
dc.subject.mesh*Genomicsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshNeoplasm Proteins/*analysisen_GB
dc.subject.mesh*Proteomicsen_GB
dc.subject.meshSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionizationen_GB
dc.subject.meshTumor Markers, Biological/analysisen_GB
dc.titleGenomic and oncoproteomic advances in detection and treatment of colorectal cancer.en_GB
dc.contributor.departmentDept. of Surgery, Our Lady of Lourdes Hospital, Drogheda, County Louth, Ireland. , seamusmchugh@rcsi.ieen_GB
dc.identifier.journalWorld journal of surgical oncologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.